Benzinga··Vandana SinghAbbVie's TrenibotE Setback Raises Manufacturing Questions Amid $1.4B Plant Investment
AbbVie received FDA rejection for wrinkle drug TrenibotE over manufacturing issues, though safety and efficacy cleared. Company plans response within months.
ABBVFDA rejectionComplete Response Letter